- Home
- UROY vs ORGO Comparison
UROY vs ORGO Comparison
Compare UROY & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | ORGO |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.2M | 539.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UROY | ORGO |
|---|---|---|
| Price | $4.01 | $4.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.50 | ★ $8.00 |
| AVG Volume (30 Days) | 2.4M | ★ 3.1M |
| Earning Date | 12-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $35,266,447.00 | ★ $465,218,000.00 |
| Revenue This Year | $195.97 | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.29 | 2.24 |
| 52 Week Low | $1.43 | $2.61 |
| 52 Week High | $5.37 | $7.08 |
Technical Indicators
Market Signals| Indicator | UROY | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 47.11 |
| Support Level | $3.63 | $4.87 |
| Resistance Level | $3.87 | $5.83 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 95.60 | 6.77 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.